BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ: CELG) today announced results from an analysis of post-progression outcomes in MM-015, a phase III study of continuous REVLIMID® (lenalidomide) plus melphalan and prednisone (MPR-R, n=152) compared with a fixed cycle of MPR followed by placebo (n=153) or of melphalan and prednisone followed by placebo (MP, n-154) in newly diagnosed multiple myeloma patients.
